Non-alcoholic fatty liver disease – how to effectively fight the nowadays most common liver disease?

Czech version

Authors: Václav Šmíd
Authors‘ workplace: IV. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze
Published in: Čas. Lék. čes. 2021; 160: 65-70
Category: Review Article

Overview

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease nowadays. It is referred to as liver manifestation of metabolic syndrome. Given the growing incidence of diabetes and obesity, we can confidently say that we will be, or even are facing, a NAFLD pandemic in the near future. Despite strenuous efforts, there is no causal therapy and the only effective therapeutic modality is a complex lifestyle change encompasses diet and regime changes leading to a weight loss. However, it is clear from many published papers that putting these recommendations into practice and their long-term compliance with patients is very difficult. What can be offered to patients with NAFLD in clinical practice and how can they be rationally treated?

Keywords:

non-alcoholic fatty liver disease – NAFLD – non-alcoholic steatohepatitis – NASH – liver fibrosis – metabolic syndrome – Physical activity – Mediterranean diet – lifestyle modifications

Sources

Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10(11): 686–690.
Kwok R, Choi KC, Wong GL et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2016; 65(8): 1359–1368.
Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64(1): 73–84.
Adams LA, Anstee QM, Tilg H et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66(6): 1138–1153.
Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40(12): 1461–1465.
Krawczyk M, Rau M, Schattenberg JM et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res 2017; 58(1): 247–255.
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48(6): 1791–1798.
Ryu S, Chang Y, Jung HS et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol 2015; 63(5): 1229–1237.
Grontved A, Hu FB. Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA 2011; 305(23): 2448–2455.
Levine JA. Sick of sitting. Diabetologia 2015; 58(8): 1751–1758.
Healy GN, Dunstan DW, Salmon J et al. Breaks in sedentary time: beneficial associations with metabolic risk. Diabetes Care 2008; 31(4): 661–666.
Santaliestra-Pasias AM, Mouratidou T, Huybrechts I et al. Increased sedentary behaviour is associated with unhealthy dietary patterns in European adolescents participating in the HELENA study. Eur J Clin Nutr 2014; 68(3): 300–308.
Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56(1): 255–266.
Keating SE, Hackett DA, George J et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57(1): 157–166.
Hashida R, Kawaguchi T, Bekki M et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 2016; 66(1): 142–152.
Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2013; 129(25 Suppl 2): S102–138.
Pugh CJ, Sprung VS, Jones H et al. Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease. Int J Obes (Lond) 2016; 40(12): 1927–1930.
Cuthbertson DJ, Shojaee-Moradie F, Sprung VS et al. Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2016; 130(2): 93–104.
Shojaee-Moradie F, Cuthbertson DJ, Barrett M et al. Exercise training reduces liver fat and increases rates of VLDL clearance, but not VLDL production in NAFLD. J Clin Endocrinol Metab 2016; 101(11): 4219–4228.
Shen J, Wong GL, Chan HL et al. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2015; 30(1): 139–146.
Zelber-Sagi S, Lotan R, Shlomai A et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56(5): 1145–1151.
Koopman KE, Caan MW, Nederveen AJ et al. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial. Hepatology 2014; 60(2): 545–553.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149(2): 367–378.
Rynders CA, Thomas EA, Zaman A et al. Effectiveness of intermittent fasting and time-restricted feeding compared to continuous energy restriction for weight loss. Nutrients 2019; 11(10).
Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss Isakov N et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol 2018; 68(6): 1239–1246.
Howard BV, Wylie-Rosett J. Sugar and cardiovascular disease: a statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2002; 106(4): 523–527.
Chiu S, Mulligan K, Schwarz JM. Dietary carbohydrates and fatty liver disease: de novo lipogenesis. Curr Opin Clin Nutr Metab Care 2018; 21(4): 277–282.
Abdelmalek MF, Suzuki A, Guy C et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51(6): 1961–1971.
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al. Long-term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population-based study. J Hepatol 2007; 47(5): 711–717.
de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clin Nutr 2018; 37(1): 37–55.
Williams KH, Sullivan DR, Nicholson GC et al. Opposite associations between alanine aminotransferase and gamma-glutamyl transferase levels and all-cause mortality in type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism 2016; 65(5): 783–793.
Abenavoli L, Boccuto L, Federico A et al. Diet and non-alcoholic fatty liver disease: the Mediterranean way. Int J Environ Res Public Health 2019; 16(17).
Hyogo H, Yamagishi S, Iwamoto K et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22(7): 1112–1119.
Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67(4): 829–846.
Dunn W, Sanyal AJ, Brunt EM et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57(2): 384–391.
Hashimoto Y, Hamaguchi M, Kojima T et al. Modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study. J Gastroenterol Hepatol 2015; 30(3): 546–552.
Ascha MS, Hanouneh IA, Lopez R et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51(6): 1972–1978.
Ma J, Fox CS, Jacques PF et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol 2015; 63(2): 462–469.
Setiawan VW, Wilkens LR, Lu SC et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148(1): 118–125.
Vitaglione P, Morisco F, Mazzone G et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010; 52(5): 1652–1661.
Hoofnagle JH, Van Natta ML, Kleiner DE et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013; 38(2): 134–143.
Pickett-Blakely O, Young K, Carr RM. Micronutrients in non-alcoholic fatty liver disease pathogenesis. Cell Mol Gastroenterol Hepatol 2018; 6(4): 451–462.
Patel NS, Doycheva I, Peterson MR et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015; 13(3): 561–568.e1.
Eckard C, Cole R, Lockwood J et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol 2013; 6(4): 249–259.
Ross R, Hudson R, Stotz PJ et al. Effects of exercise amount and intensity on abdominal obesity and glucose tolerance in obese adults: a randomized trial. Ann Intern Med 2015; 162(5): 325–334.
Wing RR, Bolin P, Brancati FL et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369(2): 145–154.
Byers T, Sedjo RL. Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocr Relat Cancer 2015; 22(3): R125–R134.
Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology 2010; 51(1): 121–129.
Glass LM, Dickson RC, Anderson JC et al. Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with non-alcoholic steatohepatitis. Dig Dis Sci 2015; 60(4): 1024–1030.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388–1402.
Bellentani S, Dalle Grave R, Suppini A et al. Behavior therapy for non-alcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2008; 47(2): 746–754.
Amor AJ, Perea V. Dyslipidemia in non-alcoholic fatty liver disease. Curr Opin Endocrinol Diabetes Obes 2019; 26(2): 103–108.
Goh GB, Pagadala MR, Dasarathy J et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int 2015; 35(3): 979–85.
Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N Engl J Med 2010; 362(18): 1675–1685.
Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol 2012; 36 Suppl 1: S41–S45.
Brůha R, Dvořák K, Fejfar T et al. Doporučený postup České hepatologické společnosti ČLS JEP pro diagnostiku a léčbu nealkoholové tukové choroby jater (NAFLD). Gastroent Hepatol 2020; 74(2): 103–110.

Labels

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

Allocation of scarce resources in a pandemic

COVID-19 antibody testing: examination of the antibody response to coronavirus in common practice

Stress management techniques for healthcare workers as an important professional tool to fight (not only) COVID-19 pandemics

Use of cognitive-behavioral approach to overweight and obesity therapy in STOB activities

ATP-sensitive potassium channels: key players in pathophysiology of many diseases

The risk of insect-borne diseases transmission in the Czech Republic and Slovakia

Principles of evidence-based medicine: from Robert Koch’s postulates to a current EBM concept

On the origins of European gynaecology: the archaeological and literary sources to the development of gynaecology in Greece before 500 BC

Computer vision syndrome – symptoms and prevention

Gertrude Belle Elionová (1918–1999)

Zamyšlení nad Spolkem českých lékařů v Praze

K devadesátinám prof. MUDr. Jany Pařízkové, DrSc.